Cargando…
Rituximab-Related Pulmonary Toxicity
We report the case of an 80-year-old man treated for follicular grade 3B non-Hodgkin’s lymphoma (NHL). Immunochemotherapy consisted of rituximab (375 mg/m(2)) and CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) every 21 days. Since the patient complained of mild dyspnea on effort wi...
Autores principales: | Herishanu, Yair, Perry, Chava, Polliack, Aaron |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123637/ http://dx.doi.org/10.1007/978-3-642-15742-4_64 |
Ejemplares similares
-
COVID-19 in patients with CLL: how can we change the odds?
por: Herishanu, Yair, et al.
Publicado: (2021) -
Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia
por: Shapiro, Mika, et al.
Publicado: (2017) -
REGEN‐COV antibody combination in patients with lymphoproliferative malignancies and SARS‐CoV‐2 infection
por: Bronstein, Yotam, et al.
Publicado: (2022) -
Rituximab-related Severe Toxicity
por: Ghrenassia, E., et al.
Publicado: (2018) -
Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy
por: Cohen, Dan, et al.
Publicado: (2021)